Sandoz Gmbh

Novartis Ag

Theodor Fehr

Paul A Stadler

Peter Stutz

Berndt Oberhauser

Walter Schuler

Michael Morris Dreyfuss

Hartmut Hauth

Lukas Oberer

Valerie Quesniaux Ryffel

Dieter Geyl

Carolyn Ann Foster

Jean-Jacques Sanglier

Macrolides

Cyclopeptolides

The compounds of formula I ##STR1## wherein either

Substituted 4-azatricyclo(22.3.1.0.sup.4,9)octacos-18-ene derivatives,

This invention provides new compounds of formula I, ##STR1## wherein X is hydrogen, chlorine or bromine,

8.alpha.-Substituted ergoline-I derivatives

The present invention provides compounds of formula I, ##STR1## wherein X is hydrogen, chlorine or bromine,

Sulfonamido and sulfamoylamino-ergoline-I derivatives

This invention provides new compounds of formula I, ##STR1## wherein R is branched chain alkyl of 3 to 6 carbon atoms, useful as venoconstrictors and venotonics.

Ergopeptine derivatives

This invention provides new compounds of formula I, ##STR1## wherein R.sub.1 is alkyl or 2 to 5 carbon atoms, and

6-Branched chain alkyl sustituted ergot alkaloids

This invention provides new compounds of formula I, ##STR1## wherein R.sub.1 is hydrogen, alkyl of 2 to 8 carbon atoms, or phenylalkyl of 7 to 9 carbon atoms, and

6-Hydrocarbon-ergopeptines

The present invention concerns novel 13-bromo-lysergic acid compounds of formula I: ##STR1## wherein R.sub.2 is isopropyl, 1 or 2-methylpropyl or benzyl, useful as agents for the treatment of cerebral insufficiency.

Growing community of inventors

Dornach, Switzerland

Theodor Fehr